A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Latest Information Update: 30 May 2025
At a glance
- Drugs Encorafenib (Primary) ; PF-07799544 (Primary) ; PF-07799933 (Primary) ; Tinlorafenib (Primary)
- Indications Brain cancer; Malignant melanoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 22 May 2025 Planned End Date changed from 27 Apr 2029 to 14 May 2029.
- 22 May 2025 Planned primary completion date changed from 25 Oct 2027 to 11 Nov 2027.
- 17 Apr 2025 Planned End Date changed from 12 Jun 2029 to 27 Apr 2029.